---
title: "BOYA BIOLOGY: Approved for the supplemental application of intravenous immunoglobulin drug"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/242564548.md"
description: "BOYA BIOLOGY announced that the company recently received the \"Drug Supplement Application Approval Notice\" issued by the National Medical Products Administration, agreeing to increase the specification of intravenous human immunoglobulin to 5g/bottle and issuing the drug approval number. As of now, the total R&D investment for this drug is approximately 48.29 million yuan. This approval will further enrich the company's product pipeline and enhance its profitability and market competitiveness"
datetime: "2025-05-30T10:34:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/242564548.md)
  - [en](https://longbridge.com/en/news/242564548.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/242564548.md)
generator: "portal-rs"
---

# BOYA BIOLOGY: Approved for the supplemental application of intravenous immunoglobulin drug

BOYA BIOLOGY announced that the company recently received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration, agreeing to increase the specification of intravenous human immunoglobulin to 5g/bottle and issuing the drug approval number. As of now, the total R&D investment for this drug is approximately 48.29 million yuan. This approval will further enrich the company's product pipeline and enhance its profitability and market competitiveness

### Related Stocks

- [300294.CN](https://longbridge.com/en/quote/300294.CN.md)

## Related News & Research

- [Syngenta files for Hong Kong IPO, aiming to raise at least $5 billion, sources say](https://longbridge.com/en/news/299027959.md)
- [MegaGen Announces Launch of BLUEDIAMOND ZYGOMA Implant at the 2026 NASM Symposium in Chicago](https://longbridge.com/en/news/299063618.md)
- [Breakthrough T1D-Convened Paper Outlines First International Consensus Guidance on General Population Screening for Early-Stage Type 1 Diabetes](https://longbridge.com/en/news/298647019.md)
- [Precise Biometrics Extends IOTRUST Partnership for Next-Gen DCENT Crypto Wallets](https://longbridge.com/en/news/299006377.md)
- [REG - Cadence Minerals PLC - Azteca Cold and Wet Commissioning Underway](https://longbridge.com/en/news/298909508.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**